Who is sponsoring NCT05412732?

NCT05412732 is sponsored by Instituto de Investigación Hospital Universitario La Paz.

What drugs are being tested in NCT05412732?

Interventions in NCT05412732: prospective biomedical research study.

What condition does NCT05412732 study?

NCT05412732 studies Infections in Acute Myocardial Infarction Patients.

Is NCT05412732 still recruiting?

NCT05412732 is currently status unknown. Last updated 9 June 2022.

Last reviewed 2022-06-09 · How we verify

NCT05412732

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study for the Validation of a New Biomarker to Determine Predisposition to Infections in Patients With Acute Myocardial Infarction.

Status unknown Last updated 9 June 2022

What this trial tests

trial testing prospective biomedical research study in Infections in Acute Myocardial Infarction Patients in 300 participants. Status unknown.

Timeline

21 July 2021

Primary endpoint
21 July 2022

21 July 2023

Quick facts

Lead sponsor	Instituto de Investigación Hospital Universitario La Paz
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	21 July 2021
Primary completion	21 July 2022
Estimated completion	21 July 2023
Sites	1 location across Spain

Drugs / interventions tested

prospective biomedical research study

Conditions studied

Infections in Acute Myocardial Infarction Patients — all drugs for Infections in Acute Myocardial Infarction Patients →

Sponsor

Instituto de Investigación Hospital Universitario La Paz

Who can join

Adults 18 to 100, any sex, with Infections in Acute Myocardial Infarction Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective biomedical research study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Instituto de Investigación Hospital Universitario La Paz trials

Trials by the same sponsor.

NCT06709469 — Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescent · Phase 1 · recruiting
NCT06701825 — Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus · Phase 4 · recruiting
NCT06488898 — Abdominal Aortic Aneurysm Stabilization With Truncal Cells: Controlled Clinical Trial With Historical Cohorts · Phase 2 · recruiting
NCT06273306 — Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC) · NA · not yet recruiting
NCT06302647 — Assessing Interest in Web/App Platforms for Early Phase Clinical Trial Recruitment · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05412732 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto de Investigación Hospital Universitario La Paz
Last refreshed: 9 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05412732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing